⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SGMT News
Sagimet Biosciences Inc. Series A Common Stock
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
SGMT
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
globenewswire.com
SGMT
Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025
globenewswire.com
SGMT
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
globenewswire.com
SGMT
Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration
prnewswire.com
SGMT
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
globenewswire.com
SGMT
Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025
prnewswire.com
SGMT